Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAMIAI is a well-known Chinese brand primarily offering probiotic products for infants and children. Its flagship product is a combination of live beneficial bacteria, specifically Bacillus subtilis (R-179) and Enterococcus faecium (R-026), along with a blend of multivitamins (Vitamin C, B1, B2, B6, B12, Niacinamide) and trace elements (Calcium, Zinc). It is designed to support digestive health and improve gut flora in babies and young children. The product works by regulating the intestinal environment, promoting the growth of normal intestinal flora, and inhibiting pathogenic bacteria, while also supplementing essential vitamins and minerals. It is indicated for various digestive issues such as diarrhea, constipation, dyspepsia, and intestinal flora imbalance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MAMIAI.